Status:
COMPLETED
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
Lead Sponsor:
Baylor College of Medicine
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is: * To identify the common factor for L5 prevalence in patients with Metabolic Syndrome. * To determine whether Ezetimibe, Simvastatin, and Vytorin can correct the L5- pro...
Detailed Description
Epidemiological evidence indicates that metabolic syndrome (MS) is a strong predisposing condition for atherosclerosis. Elevation of plasma low-density lipoprotein (LDL) cholesterol(LDL-C) concentrati...
Eligibility Criteria
Inclusion
- Participants who meet 3 or more of the 5 criteria specified in the ATPIII guidelines will be recruited.
- The 5 criteria are:
- abdominal obesity (men\>40 inches, women \>35 inches);
- TG\> 150mg/dL;
- low HDL-C (men \< 40mg/dL, women \< 50 mg/dL);
- high blood pressure (\>or=130/\>or=85 mmHg);
- fasting glucose \> or = 110mg/dL.
- People with different ethnic backgrounds will be included.
Exclusion
- symptomatic coronary artery disease
- peripheral vascular disease
- cerebral ischemia (stroke)
- smoking
- hypothyroidism
- kidney diseases
- consumption of antioxidation supplements/drugs or use of lipid-lowering drugs in the last 3 months
- women who are pregnant, nursing, or planning to become pregnant
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00988364
Start Date
March 1 2007
End Date
February 1 2008
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Baylor College of Medicine
Houston, Texas, United States, 77030